Friday, October 30, 2026

Palladium Futures Bearish Momentum With A 11% Slide In The Last 10 Sessions

ViaNews Editorial Team

February 12, 2024

Palladium Futures Bearish Momentum With A 11% Slide In The Last 10 Sessions

(VIANEWS) - Palladium (PA) has been up by 11.48% for the last 10 sessions. At 19:53 EST on Sunday, 11 February, Palladium (PA) is $867.50.

Volume

Today's last reported volume for Palladium is 144, 99.99% below its average volume of 3803622097.92.

Volatility

Palladium's last week, last month's, and last quarter's current intraday variation average was 0.87%, 0.39%, and 1.89%, respectively.

Palladium's highest amplitude of average volatility was 2.22% (last week), 1.50% (last month), and 1.89% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palladium's commodity is considered to be oversold (<=20).

News about

  • WTI crude oil weekly forecast: prices edged higher going into last weekend - 11 February 2024. According to DailyForex on Sunday, 11 February, "While facing selling pressure this past Friday with four short-term technical fights lower, WTI Crude Oil was able to bounce off the 76.000 level rather well. ", "After surpassing the 76.000 mark of Thursday, then challenging the 76.500 ratio early on Friday and then bursting above the 77.000 USD level momentarily, the commodity was pushed backwards.76.000 WTI Crude Oil Support for Short-Term Considerations"

More news about Palladium (PA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com